MDPI and ACS Style
Benedetti, E.; Baratè, C.; Mavilia, F.; Bramanti, E.; Morganti, R.; Guerri, V.; Cervetti, G.; Capochiani, E.; Bertaggia, I.; Stella, S.M.;
et al. Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Treated with Fixed Duration Venetoclax-Rituximab: Assessment of Response with Ultrasound, and Relationship with Minimal Residual Disease. J. Clin. Med. 2023, 12, 1772.
https://doi.org/10.3390/jcm12051772
AMA Style
Benedetti E, Baratè C, Mavilia F, Bramanti E, Morganti R, Guerri V, Cervetti G, Capochiani E, Bertaggia I, Stella SM,
et al. Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Treated with Fixed Duration Venetoclax-Rituximab: Assessment of Response with Ultrasound, and Relationship with Minimal Residual Disease. Journal of Clinical Medicine. 2023; 12(5):1772.
https://doi.org/10.3390/jcm12051772
Chicago/Turabian Style
Benedetti, Edoardo, Claudia Baratè, Fabrizio Mavilia, Emilia Bramanti, Riccardo Morganti, Valentina Guerri, Giulia Cervetti, Enrico Capochiani, Ilaria Bertaggia, Salvatore Massimo Stella,
and et al. 2023. "Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Treated with Fixed Duration Venetoclax-Rituximab: Assessment of Response with Ultrasound, and Relationship with Minimal Residual Disease" Journal of Clinical Medicine 12, no. 5: 1772.
https://doi.org/10.3390/jcm12051772
